Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1994 1
1995 1
1996 1
1999 2
2001 1
2003 2
2004 13
2005 27
2006 16
2007 26
2008 26
2009 18
2010 12
2011 12
2012 22
2013 17
2014 14
2015 29
2016 36
2017 36
2018 38
2019 53
2020 33
2021 51
2022 40
2023 56
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean b raimi (6 results)?
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.
BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. METHODS: In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell …
BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoim …
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
METHODS: In this trial, we randomly assigned patients with early relapsed or refractory large B-cell lymphoma in a 1:1 ratio to receive either axi-cel or standard care (two to three cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem-cell t …
METHODS: In this trial, we randomly assigned patients with early relapsed or refractory large B-cell lymphoma in a 1:1 ratio to recei …
Urethral Stricture Disease Guideline Amendment (2023).
Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Wessells H, et al. J Urol. 2023 Jul;210(1):64-71. doi: 10.1097/JU.0000000000003482. Epub 2023 Apr 25. J Urol. 2023. PMID: 37096574 Review.
Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.
Stähli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, Kesterke R, Nordbeck P, Witzenbichler B, Lang IM, Kessler M, Valina C, Dibra A, Rohla M, Moccetti M, Vercellino M, Gaede L, Bott-Flügel L, Jakob P, Stehli J, Candreva A, Templin C, Schindler M, Wischnewsky M, Zanda G, Quadri G, Mangner N, Toma A, Magnani G, Clemmensen P, Lüscher TF, Münzel T, Schulze PC, Laugwitz KL, Rottbauer W, Huber K, Neumann FJ, Schneider S, Weidinger F, Achenbach S, Richardt G, Kastrati A, Ford I, Maier W, Ruschitzka F; MULTISTARS AMI Investigators. Stähli BE, et al. N Engl J Med. 2023 Oct 12;389(15):1368-1379. doi: 10.1056/NEJMoa2307823. Epub 2023 Aug 27. N Engl J Med. 2023. PMID: 37634190 Clinical Trial.
A human model of asthma exacerbation reveals transcriptional programs and cell circuits specific to allergic asthma.
Alladina J, Smith NP, Kooistra T, Slowikowski K, Kernin IJ, Deguine J, Keen HL, Manakongtreecheep K, Tantivit J, Rahimi RA, Sheng SL, Nguyen ND, Haring AM, Giacona FL, Hariri LP, Xavier RJ, Luster AD, Villani AC, Cho JL, Medoff BD. Alladina J, et al. Sci Immunol. 2023 May 12;8(83):eabq6352. doi: 10.1126/sciimmunol.abq6352. Epub 2023 May 5. Sci Immunol. 2023. PMID: 37146132 Free PMC article.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
Biochemistry, Adiponectin.
Ramakrishnan N, Auger K, Rahimi N, Jialal I. Ramakrishnan N, et al. 2023 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725726 Free Books & Documents.
AdipoRs are expressed in most tissues, including immune cells such as monocytes, B cells, and NK cells. However, AdipoR1 is mainly expressed in skeletal muscle, while AdipoR2 is mostly expressed in the liver. ...
AdipoRs are expressed in most tissues, including immune cells such as monocytes, B cells, and NK cells. However, AdipoR1 is mainly ex …
Synthetic biology tools for environmental protection.
Aminian-Dehkordi J, Rahimi S, Golzar-Ahmadi M, Singh A, Lopez J, Ledesma-Amaro R, Mijakovic I. Aminian-Dehkordi J, et al. Biotechnol Adv. 2023 Nov;68:108239. doi: 10.1016/j.biotechadv.2023.108239. Epub 2023 Aug 22. Biotechnol Adv. 2023. PMID: 37619824 Free article. Review.
Human APOBEC3 Variations and Viral Infection.
Sadeghpour S, Khodaee S, Rahnama M, Rahimi H, Ebrahimi D. Sadeghpour S, et al. Viruses. 2021 Jul 14;13(7):1366. doi: 10.3390/v13071366. Viruses. 2021. PMID: 34372572 Free PMC article. Review.
Human APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) enzymes are capable of inhibiting a wide range of endogenous and exogenous viruses using deaminase and deaminase-independent mechanisms. These enzymes are essential components of our innate immune s …
Human APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) enzymes are capable of inhibiting a wide range of endogeno …
544 results